The European Union Approves Merck's Keytruda In Combination With Padcev As Neoadjuvant Treatment And Then Continued After Radical Cystectomy As Adjuvant Treatment, For Adults With Resectable Muscle-invasive Bladder Cancer Who Are Ineligible For Cisplatin-containing Chemotherapy

Loading news article.

The European Union Approves Merck's Keytruda In Combination With Padcev As Neoadjuvant Treatment And Then Continued After Radical Cystectomy As Adjuvant Treatment, For Adults With Resectable Muscle-invasive Bladder Cancer Who Are Ineligible For Cisplatin-containing Chemotherapy | WAPE

The European Union Approves Merck's Keytruda In Combination With Padcev As Neoadjuvant Treatment And Then Continued After Radical Cystectomy As Adjuvant Treatment, For Adults With Resectable Muscle-invasive Bladder Cancer Who Are Ineligible For Cisplatin-containing Chemotherapy

Article summary

Related companies

Comments —